SCHEMBL2794993

SCHEMBL2794993

CC(C)(C)[C@H](NC(=O)C(CC1CCCC1)CN(O)C=O)C(=O)N1CCC(Nc2ccc(C#N)cc2)CC1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MLNR O43193 2/20 0.39
MMP1 P03956 4/20 0.37
MMP13 P45452 2/20 0.37
PDF Q9HBH1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2794988 1.00 MLNR (0.39) MLNRMMP1MMP13PDF
SCHEMBL13231015 0.90 MMP1 (0.39) MMP1MMP13
SCHEMBL2790678 0.90 MMP1 (0.39) MMP1MMP13
SCHEMBL2790679 0.90 MMP1 (0.39) MMP1MMP13
SCHEMBL4602310 0.90 NPC1 (0.43) MMP1MMP13
SCHEMBL4886956 0.90 NPC1 (0.43) MMP1MMP13
SCHEMBL2795549 0.90 CTSS (0.40) MLNRMMP1MMP13
SCHEMBL2795556 0.90 CTSS (0.40) MLNRMMP1MMP13
SCHEMBL2795032 0.90 MMP1 (0.45) MMP1MMP13
SCHEMBL2795037 0.90 MMP1 (0.45) MMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168421-A1 A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2010-07-01 US disclosed
EP-2164829-A1 A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF Ildong Pharmaceutical Co., Ltd. (KR) 2010-03-24 EP disclosed
WO-2008150089-A1 A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF ILDONG PHARMACEUTICAL CO., LTD. (KR) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168421-A1 A NEW PEPTIDE DEFORMYLASE INHIBITOR COMPOUND AND MANUFACTURING PROCESS THEREOF PDF, PEPD, DPEP1 MLNR 1763/4885MMP1 2274/4885MMP13 2075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.